An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma
Conditions: Large B-cell Lymphoma; B-cell Lymphoma Interventions: Drug: Magrolimab; Drug: Rituximab; Drug: CAR T leukapheresis; Drug: Radiation Sponsor: M.D. Anderson Cancer Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials